Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) EBIT Margin (2016 - 2025)

Haemonetics (HAE) has 17 years of EBIT Margin data on record, last reported at 19.88% in Q4 2025.

  • For Q4 2025, EBIT Margin rose 295.0% year-over-year to 19.88%; the TTM value through Dec 2025 reached 19.05%, up 591.0%, while the annual FY2025 figure was 16.3%, 370.0% up from the prior year.
  • EBIT Margin reached 19.88% in Q4 2025 per HAE's latest filing, up from 17.87% in the prior quarter.
  • Across five years, EBIT Margin topped out at 21.58% in Q1 2025 and bottomed at 9.41% in Q2 2021.
  • Average EBIT Margin over 5 years is 12.31%, with a median of 13.7% recorded in 2022.
  • Peak YoY movement for EBIT Margin: plummeted -2031bps in 2021, then skyrocketed 1665bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 10.22% in 2021, then soared by 39bps to 14.18% in 2022, then decreased by -4bps to 13.67% in 2023, then grew by 24bps to 16.94% in 2024, then grew by 17bps to 19.88% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 19.88% in Q4 2025, 17.87% in Q3 2025, and 16.76% in Q2 2025.